Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bilastine · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bilastine 20mg once per day |
| 2 | EXPERIMENTAL | Bilastine 20mg twice per day |
| 3 | EXPERIMENTAL | Bilastine 10mg once per day |
| 4 | EXPERIMENTAL | Bilastine 10mg twice per day |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bilastine | DRUG | Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets |
| Placebo | DRUG | Placebo tablets twice daily for 14 days |
Inclusion Criteria: * clinical history of Seasonal Allergic Rhinoconjunctivitis with seasonal onset and offset of nasal allergy symptoms * documentation of a positive skin test within one year of screening to Mountain Cedar allergen Exclusion Criteria: * significant medical condition * significan...
Bilastine is an investigational small molecule being studied for the symptomatic treatment of seasonal allergic rhinitis, also known as hay fever. It is being evaluated in the therapeutic area of ophthalmology. The drug is currently in Phase 2 clinical development and is not approved by the FDA.
Bilastine is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's efficacy and safety for the treatment of seasonal allergic rhinitis.
Bilastine is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
Bilastine has one completed clinical trial registered under NCT00574379. This Phase 2 study evaluated the efficacy, safety, and pharmacokinetics of once or twice daily Bilastine (10 or 20 mg) compared with placebo in the symptomatic treatment of seasonal allergic rhinitis. The trial enrolled 805 participants in the United States.
Bilastine is a distinct investigational drug being developed by Merck & Company, Inc. No alternative names for Bilastine have been reported in the clinical trial data. It is being studied specifically for seasonal allergic rhinitis and associated conditions such as allergic conjunctivitis.